Rational 'Co-Design' of Targeted Anticancer Therapeutics
Integrating Immuno-Oncology, Biomaterials, and Translational Systems
- 1st Edition - March 1, 2027
- Latest edition
- Editors: Y. Manojkumar, Rajadurai Vijay Solomon, Sudarshan Singh, Elif Damla Arısan
- Language: English
Rational 'Co-Design' of Targeted Anticancer Therapeutics: Integrating Immuno Oncology, Biomaterials, and Translational Systems presents a unified, system level framework that d… Read more
Description
Description
Key features
Key features
- Provides a rational drug–biomaterial co design framework linking molecular properties to carrier selection and delivery strategy
- Integrates computational tools (quantum chemistry, MD, ADMET, AI/ML) with experimental validation and decision frameworks
- Addresses translational realities—toxicity, immunogenicity, regulatory pathways, manufacturing, cost, and sustainability
Readership
Readership
Table of contents
Table of contents
2. Anticancer Therapeutics as Integrated Systems
3. Molecular Features Governing Targeting and Deliverability
4. Electronic Structure–Driven Optimization of Anticancer Molecules
5. Predictive Modeling of Drug–Target Interactions
6. Modeling Drug–Biomaterial Interactions
7. Targeted Anticancer Drug Delivery – Computational Perspective
8. Molecular Dynamics and ADMET in Therapeutic System Design
9. Redefining Natural Biomaterials in Anticancer Therapy
10. Rational Selection of Natural Biomaterials for Therapeutic Systems
11. Engineering Natural Polymers for Molecular Recognition
12. Designing Mucoadhesive Anticancer Therapeutic Systems
13. Transdermal Anticancer Therapeutic Systems
14. Controlled and Sustained Release as a Molecular Property
15. Integrating Computational Design with Experimental Formulation
16. Decision Making Frameworks for Drug–Biomaterial Co Design
17. Toxicity and Safety at the Drug–Carrier Interface
18. Affordability, Scalability, and Sustainability in Therapeutic Design
19. AI and ML for Anticancer Drug Delivery
20. Future Directions in System Level Anticancer Therapeutics
Product details
Product details
- Edition: 1
- Latest edition
- Published: March 1, 2027
- Language: English
About the editors
About the editors
YM
Y. Manojkumar
Dr. Y. Manojkumar is an Assistant Professor of Chemistry at Bishop Heber College, Tiruchirappalli, India. He earned a Ph.D. in Chemistry from Bharathidasan University, specializing in metal-based anticancer therapeutics, biomolecular interactions, and nanomaterials, and conducted postdoctoral research at Gebze Technical University, Turkey, supported by a TÜBİTAK Fellowship. His research spans metallodrug design, anticancer nanomaterials, computational modeling, and biomaterial-based drug delivery. He has published in renowned journals and contributed chapters and edited volumes with major publishers. His cobalt(III) Schiff base work has received notable recognition. He holds patents in India and the UK and has led funded research collaborations at national and international levels. He mentors students and contributes as a reviewer for leading journals. An Ambassador of the European Association for Cancer Research, he actively engages in science outreach, rural development, and interdisciplinary translational research.
RS
Rajadurai Vijay Solomon
Dr. Rajadurai Vijay Solomon is a faculty member in the Department of Chemistry at Madras Christian College, where he teaches physical chemistry to undergraduate and postgraduate students. He joined MCC after postdoctoral research in the United States and Switzerland and earned a PhD in computational chemistry from Bharathidasan University. His research spans computational chemistry and its applications in chemical biology and materials. He has received recognitions including early career research awards, institutional and alumni publications awards, and a national-level outstanding professor award. He has been recognized as a Young Scientist by a regional academy for his research outputs. He has published extensively, contributed book chapters, edited volumes, and delivered numerous invited lectures. He serves as a reviewer for leading journals and sits on the editorial board of Scientific Reports. He currently mentors PhD students.
SS
Sudarshan Singh
Dr. Sudarshan Singh is a Frontier Proactive Research scholar at the Faculty of Pharmacy, Chiang Mai University, Thailand. He holds five patents, is approved as a PhD guide by Pacific University, Rajasthan, and is a life member of bodies including the Society of Pharmacovigilance India. He has received research and travel grants from the governments of Gujarat, ICMR, and other institutions.
His current research focuses on 3D-printed implantable green composites with polymeric biomaterials to address dermal inflammation, alongside multifunctional biomaterial development for drug delivery. Previous work involved lipid vesicular curcuminoid analogues as biodegradable scaffolds for intracellular uptake and anti-inflammatory response studies. His postdoctoral work at Prince of Songkhla University centered on biodegradable antibacterial nanoparticle wound dressings tested across multiple cell lines.
Dr. Singh is proficient in a wide range of analytical techniques, including SEM-EDX, NMR, XRD, HPLC, LC-MS, confocal microscopy, and flow cytometry.
EA
Elif Damla Arısan
Prof. Elif Damla Arısan is Vice Rector of Gebze Technical University, Türkiye, overseeing research, innovation, sustainability, science communication, and institutional impact. She leads the Women and Family Studies Centre, Sustainability Unit, and Science Communication Unit, and founded DapGENOMICS and Futuroscopic Kids, actively pursuing bioentrepreneurship and public engagement in science. She earned a Ph.D. in Biological Sciences and Bioengineering from Sabancı University and completed advanced cancer biology training at Harvard. Her research spans cancer cell biology, drug resistance, signaling, autophagy, personalized medicine, and nanotechnology-based drug delivery. She has published extensively in high-impact journals and authored or edited numerous books and chapters. She holds international patents in anticancer therapeutics and aptamer-based targeting. She leads multiple funded projects and collaborates across academia and industry. She mentors researchers, organizes international conferences, serves on editorial boards, and reviews for many journals. She contributes to policy-level science communication through national bodies.